Kristian Humer compensation by year
Foghorn Therapeutics Summary Compensation Table · the one fiscal year held| Component | FY2024 |
|---|---|
| Salary | $336,458 |
| Bonus | $87,000 |
| Stock awards | $0 |
| Option awards | $1,250,797 |
| Non-equity incentive | $161,500 |
| Pension and deferred compensation | $0 |
| All other | $52,848 |
| Total | $1,888,603 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Foghorn Therapeutics Inc. DEF 14A filed May 5, 2025, accession 0001193125-25-112091, and prior-year filings.
How this page was built: the Foghorn Therapeutics Inc. filed document, accession 0001193125-25-112091. Every figure is read from that document and cited to the page and table it appears in. Filed May 5, 2025.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 275,000 | — | $6.03 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Foghorn Therapeutics Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Foghorn Therapeutics’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Kristian Humer · this page | Chief Financial Officer | $1,888,603 |
| Adrian Gottschalk | President and Chief Executive Officer | $1,559,562 |
| Anna Rivkin | Chief Business Officer | $1,472,584 |
| Steven Bellon | Chief Scientific Officer | $902,212 |
| Alfonso Quintas-Cardama | Chief Medical Officer | $769,489 |
The full Foghorn Therapeutics compensation record
free company briefThis page is one person within Foghorn Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Foghorn Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.